Flexible Design, Good Radial Force Make Misago RX Stent Suitable For Peripheral Arteries

The stent has shown to be easily positioned across different lesions because of its high flexibility and maintains strength over considerable time periods

Terumo has planned to release Misago RX in the U.S. Misago® is a peripheral self-expanding stent system consisting of a rapid exchange delivery catheter and a pre-mounted stent made of nitinol. //

The bare stent is made of nitinol, a common shape memory alloy used for such applications. Using a thumbwheel, the stent is deployed, casting away the need for other delivery devices.

Drug-Eluting Stents
Drug-eluting stents are scaffolds containing drug on their surface placed in the coronary arteries.

The stent has shown to be easily positioned across different lesions because of its high flexibility and maintains strength over considerable time periods.

FDA approval was based on submission of one-year data from the Occlusive/Stenotic Peripheral Artery Revascularization Study (OSPREY). The study findings indicate a low potential for stent fracture, simplified delivery system and 88.6% freedom from target lesion revascularization.

Dr. John Fritz Angle, Principal Investigator for the U.S. clinical trial said, "The MISAGO stent has a flexible design and good radial force that we found performed well in the superficial femoral artery. Peripheral artery disease can have devastating consequences but we believe the MISAGO stent offers a durable treatment option for superficial femoral artery disease."

Prices of Stents are Inflated by Upto 700% for Distributors, Doctors and Hospitals
In the light of the findings, the FDA has written to the National Pharmaceutical Pricing Authority to bring stents under essential medicines.

Source-Medindia

Scientists Develop Bioresorbable Stents With Drug-delivering Nanoparticles
Several companies are now focusing on using biodegradable scaffolds that completely break down into smaller components to be reabsorbed by the body.

Benefits in Selective Use of Drug-eluting Stents
Limiting the use of drug-eluting stents to a selected group of patients saves money and do not increase death or heart attack risk.